The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders
Open accessAbstract
SUMMARY: Clioquinol was produced as a topical antiseptic and marketed as an oral intestinal amebicide in 1934, being used to treat a wide range of intestinal diseases. In the early 1970s, it was withdrawn from the market as an oral agent because of its association with subacute myelo‐optic neuropathy (SMON), a syndrome that involves sensory and motor disturbances in the lower limbs and visual changes. The first methods for determining plasma and tissue clioquinol (5‐chloro‐7‐iodo‐8‐quinolinol) levels were set up in the 1970s and involved HPLC separation with UV detection, these were followed by a more sensitive GC method with electron capture detection and a gaschromatographic‐massspectrometric (GC‐MS) method. Finally, an HPLC method using electrochemical detection has proved to be as highly sensitive and specific as the GC‐MS. In rats, mice, rabbits, and hamsters, clioquinol is rapidily absorbed and undergoes first‐pass metabolization to glucuronate and sulfate conjugates; the concentrations of the metabolites are higher than those of free clioquinol. Bioavailabilty versus intraperitoneal dosingis about 12%. Dogs and monkeys form fewer conjugates. In man, single‐dose concentrations are dose related, and the drug's half‐life is 11–14 h. There is no accumulation, and the drug is much less metabolized to conjugates. Clioquinol acts as a zinc and copper chelator. Metal chelation is a potential therapeutic strategy for Alzheimer's disease (AD) because zinc and copper are involved in the deposition and stabilization of amyloid plaques, and chelating agents can dissolve amyloid deposits in vitro and in vivo . In general, the ability of clioquinol to chelate and redistribute metals plays an important role in diseases characterised by Zn, Cu, Fe dyshomeostasis, such as AD and Parkinson's disease, as it reduces oxidation and the amyloid burden. Zinc chelators may also act as anticancer agents. Animal toxicity studies have revealed species‐specific differences in neurotoxic responses that are related to the serum levels of clioquinol and metabolites. This is also true in humans, who form fewer conjugates. The results of studies of Alzheimer patients are conflicting and need further confirmation. The potential therapeutic role of the two main effects of MPACs (the regulation of the distribution of metals and antioxidants) has not yet been fully explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“Metal chelation is a potential therapeutic strategy for Alzheimer’s disease (AD) because all three metals are involved in the deposition and stabilization of amyloid plaques, and chelating agents can dissolve amyloid deposits by preventing metal-Aß interactions [28,29].”
BackgroundRitchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Bush, A. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00073-3 · Cited by 731
The redox chemistry of the Alzheimer's disease amyloid β peptide
Smith, D. G., Cappai, R., & Barnham, K. J. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.02.002 · Cited by 608
Aqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion
Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., & Bush, A. I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23223 · Cited by 482
House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., & Exley, C. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6310 · Cited by 294
New Insights on How Metals Disrupt Amyloid β-Aggregation and Their Effects on Amyloid-β Cytotoxicity
Yoshiike, Y., Tanemura, K., Murayama, O., Akagi, T., Murayama, M., Sato, S., Sun, X., Tanaka, N., & Takashima, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010706200 · Cited by 244
Ha, C., Ryu, J., & Park, C. B. (2007) · Biochemistry · doi:10.1021/bi7000032 · Cited by 231
Treatment of Alzheimer’s Disease with Clioquinol
Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjögren, M., Wallin, A., Xilinas, M., & Gottfries, C.-G. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051288 · Cited by 220
Research works printed but not linked: 46
- Tateishi J, 2000, Subacute myelo‐optic‐neuropathy: Clioquinol intoxication in humans and animals, Neuropathology, 20, 520, 10.1046/j.1440-1789.2000.00296.x · DOI
- 10.1016/S0140-6736(71)92699-7 · DOI
- Gilland O, 1984, A neurological evaluation of purported cases of SMON in Sweden, Acta Neurol Scand Suppl, 100, 165
- 10.1126/science.290.5495.1273a · doi:10.1126/science.290.5495.1273a
- Meade TW, 1975, Subacute myelo‐optic neuropathy and clioquinol, Br J Prev Soc Med, 29, 157
- 10.1111/j.1749-6632.2000.tb06938.x · DOI · Paper page
- Huckle R, 2005, PBT‐1 Prana Biotechnology, Curr Opin Invest Drugs, 6, 99
- 10.3233/JAD-2008-15208 · DOI · Paper page
- 10.1016/S0378-4347(00)86047-8 · doi:10.1016/s0378-4347(00)86047-8
- 10.1248/bpb1978.6.881 · DOI
- 10.1016/S0378-4347(00)85072-0 · doi:10.1016/s0378-4347(00)85072-0
- 10.1002/jps.2600621204 · doi:10.1002/jps.2600621204
- 10.1248/cpb.24.2007 · doi:10.1248/cpb.24.2007
- 10.1007/BF00295093 · DOI
- 10.1016/S0731-7085(01)00504-0 · doi:10.1016/s0731-7085(01)00504-0
- 10.1016/j.jchromb.2006.04.014 · DOI
- 10.1248/cpb.24.2007 · doi:10.1248/cpb.24.2007
- 10.1248/cpb.24.2589 · doi:10.1248/cpb.24.2589
- 10.1248/cpb.24.2603 · doi:10.1248/cpb.24.2603
- 10.1211/jpp.59.3.0008 · doi:10.1211/jpp.59.3.0008
- 10.1002/jps.2600731011 · doi:10.1002/jps.2600731011
- Committee on Drugs, 1990, Clioquinol (lodochlorhydroxyquin, Vioform) and lodoquinol (Diiodohydroxyquin): Blindness and Neuropathy, Pediatrics, 86, 797, 10.1542/peds.86.5.797 · DOI
- 10.1016/S0166-2236(03)00067-5 · DOI · Paper page
- Igata A, 1970, On the green pigment found in SMON patients: Two cases excreting greenish urine, Jap Med J, 2427, 25
- Takasu T, 1970, On the green tongue observed in SMON patients, Igakuno Ayumi, 72, 539
- 10.1016/j.toxlet.2008.08.015 · DOI
- Lee JY, 1999, Histochemically reactive zinc in plaques of the Swedish mutant beta‐amylodosis precursor protein transgenic mice, J Neurosci, 19, RC10, 10.1523/JNEUROSCI.19-11-j0002.1999 · DOI
- 10.1073/pnas.94.18.9866 · DOI · Paper page
- 10.1016/S0006-8993(99)02096-X · DOI · Paper page
- 10.1007/s00249-007-0244-1 · DOI
- 10.1074/jbc.M407410200 · DOI
- 10.1073/pnas.0404349101 · DOI · Paper page
- 10.1111/j.1471-4159.2009.05880.x · DOI
- Takasu T, 2003, SMON – a model of the iatrogenic disease, Rinsho Shinkeigaku, 43, 866
- Benvenisti‐Zarom L, 2004, The oxidative neurotoxicity of clioquinol, Neuro Pharmac, 49, 687
- 10.1016/j.tibs.2006.06.006 · DOI
- 10.1007/s11259-006-0054-4 · doi:10.1007/s11259-006-0054-4
- 10.1016/j.brainres.2009.05.031 · DOI
- Brown DR, 2005, Neurodegeneration and oxidative stress: Prion disease results from loss of antioxidant defence, Folia Neuropathol, 43, 229
- 10.1007/s11259-005-0055-8 · DOI
- 10.3181/0903-MR-104 · DOI
- 10.1196/annals.1306.004 · DOI · Paper page
- Ding W‐Q, 2005, Anticancer activity of the antibiotic Clioquinol, Cancer Res, 65, 3389, 10.1158/0008-5472.CAN-04-3577 · DOI · Paper page
- 10.1016/j.canlet.2008.06.011 · DOI
- 10.1254/jjp.78.55 · doi:10.1254/jjp.78.55
- Sampson EL, 2007, Metal protein attenuating compounds for the treatment of Alzheimer's disease, Cochrane Database Syst Rev, 3
Cited by
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Chen, B., Yu, P., Chan, W. N., Xie, F., Zhang, Y., Liang, L., Leung, K. T., Lo, K. W., Yu, J., Tse, G. M. K., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01679-y · Cited by 420
Oxidative stress and metal carcinogenesis
Lee, J.-C., Son, Y.-O., Pratheeshkumar, P., & Shi, X. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.002 · Cited by 275
Amikacin: Uses, Resistance, and Prospects for Inhibition
Ramirez, M., & Tolmasky, M. (2017) · Molecules · doi:10.3390/molecules22122267 · Cited by 265
Metadata
- Authors
- Bareggi, S. R., & Cornelli, U.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2010-12-27
- Volume
- 18
- Issue
- 1
- Pages
- 41-46
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1488741256
- Cited by
- 243
- References
- 13
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders. https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00231.x
- The paper
- Bareggi, S. R., & Cornelli, U. (2012). Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00231.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.